In this study, exposure to antiretroviral agents such as stavudine, didanosine, or nevirapine was not found to be associated with steatosis.
Daily cannabis use was shown to be associated with a reduced risk for liver steatosis among individuals co-infected with HIV and hepatitis C, according to the results of a recent study published in the Journal of Viral Hepatitis.
In this analysis of patients from a French cohort of people co-infected with HIV and hepatitis C, the association of steatosis and cannabis use was evaluated. Ultrasound examination was used to determine the presence of steatosis, and self-administered questionnaires collected sociobehavioral data, including cannabis use frequency.
A total of 40.1% (n=336/838) of study participants had liver steatosis. Most participants did not use or only occasionally used cannabis (74.7%), followed by daily use (14.0%) or regular use (11.7%).
Daily cannabis use was more common among patients who were negative for steatosis compared with those who were positive (16.1% vs 10.7%; P =.08). After adjusting for body mass index, hazardous alcohol consumption, and current or lifetime use of lamivudine or zidovudine, daily cannabis use was correlated with a lower risk for steatosis (adjusted odds ratio [OR] 0.64; 95% CI, 0.42-0.99; P =.046).
Other factors associated with liver steatosis included high body mass index (adjusted OR 1.93; P =.02), current or lifetime exposure for lamivudine or zidovudine (adjusted OR 1.51; P =.01), and hazardous alcohol consumption (adjusted OR 1.73; P =.03).
Author: Jessica Martin